NYSE:MNK - Mallinckrodt Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $21.65 +0.14 (+0.65 %) (As of 07/15/2018 04:00 PM ET)Previous Close$21.65Today's Range$21.2842 - $21.7452-Week Range$11.65 - $49.12Volume2.66 million shsAverage Volume3.34 million shsMarket Capitalization$1.80 billionP/E Ratio2.89Dividend YieldN/ABeta1.2 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom. Receive MNK News and Ratings via Email Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:MNK CUSIPN/A Webwww.mallinckrodt.com Phone44-0-17-8463-6700 Debt Debt-to-Equity Ratio1.00 Current Ratio2.10 Quick Ratio1.90 Price-To-Earnings Trailing P/E Ratio2.89 Forward P/E Ratio3.48 P/E Growth0.36 Sales & Book Value Annual Sales$3.22 billion Price / Sales0.56 Cash Flow$16.2782 per share Price / Cash1.33 Book Value$68.65 per share Price / Book0.32 Profitability EPS (Most Recent Fiscal Year)$7.49 Net Income$2.13 billion Net Margins57.56% Return on Equity11.59% Return on Assets4.48% Miscellaneous Employees3,900 Outstanding Shares83,080,000Market Cap$1,798.79 Mallinckrodt (NYSE:MNK) Frequently Asked Questions What is Mallinckrodt's stock symbol? Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK." How will Mallinckrodt's stock buyback program work? Mallinckrodt declared that its Board of Directors has approved a share repurchase plan on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 18.5% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued. How were Mallinckrodt's earnings last quarter? Mallinckrodt PLC (NYSE:MNK) announced its quarterly earnings results on Tuesday, May, 8th. The company reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.23. The business earned $572.60 million during the quarter, compared to the consensus estimate of $568.78 million. Mallinckrodt had a return on equity of 11.59% and a net margin of 57.56%. The business's quarterly revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.04 EPS. View Mallinckrodt's Earnings History. When is Mallinckrodt's next earnings date? Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Mallinckrodt. What price target have analysts set for MNK? 19 Wall Street analysts have issued 12-month price objectives for Mallinckrodt's shares. Their predictions range from $12.00 to $67.00. On average, they anticipate Mallinckrodt's share price to reach $30.4737 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View Analyst Ratings for Mallinckrodt. What is the consensus analysts' recommendation for Mallinckrodt? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 13 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Mallinckrodt stock? Here are some recent quotes from research analysts about Mallinckrodt stock: 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) YTD (today), total debt has decreased by roughly ~$215MM. the end of 1Q18 was 4.6x, an expected increase from last quarter, following the close of the SCMP deal., 2) MNK presented its free cash flow guidance for the first time. This is expected to be ~$0.5B in 2018. Operating cash flow in 1Q18 of ~$18MM was impacted primarily by assumed liabilities paid following the close of the SCMP transaction. MNK expects free cash flow to return to more normal levels the remainder of the year., 3) While debt reduction is MNK’s top priority with respect to capital allocation for 2018, MNK did repurchase 2.9MM shares in 1Q18." (5/8/2018) 2. Mizuho analysts commented, "We plan to remove all risk-adjusted estimates for this compound from our model after the earnings call, which will be somewhat offset by the greater than $0.15-$0.20 in dilution to adjusted earnings expected in 2018″." (5/3/2018) 3. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax. As a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018) Who are some of Mallinckrodt's key competitors? Some companies that are related to Mallinckrodt include Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM) and Ultragenyx Pharmaceutical (RARE). Who are Mallinckrodt's key executives? Mallinckrodt's management team includes the folowing people: Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)Dr. Frank Scholz, Exec. VP of Global Operations & Pres of Specialty Generics (Age 49)Mr. Hugh M. O'Neill, Exec. VP and Pres of Autoimmune & Rare Diseases (Age 55)Dr. Gary M. Phillips, Exec. VP & Chief Strategy Officer (Age 52) Has Mallinckrodt been receiving favorable news coverage? News headlines about MNK stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mallinckrodt earned a news impact score of 0.07 on Accern's scale. They also gave news stories about the company an impact score of 47.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. How do I buy shares of Mallinckrodt? Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mallinckrodt's stock price today? One share of MNK stock can currently be purchased for approximately $21.65. How big of a company is Mallinckrodt? Mallinckrodt has a market capitalization of $1.80 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe. How can I contact Mallinckrodt? Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected] MarketBeat Community Rating for Mallinckrodt (NYSE MNK)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 643 (Vote Outperform)Underperform Votes: 397 (Vote Underperform)Total Votes: 1,040MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?